Osteosarcoma Recurrent clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Olaparib With Ceralasertib in Recurrent Osteosarcoma
open to eligible people ages 12-40
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: - Olaparib - Ceralasertib
San Francisco, California and other locations
Our lead scientists for Osteosarcoma Recurrent research studies include Kieuhoa Vo.